Tesamorelin: An Approved GHRH Analogue and Its Evidence

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH): the full 44-amino-acid sequence with a trans-3-hexenoyl group added to stabilise it. Unlike most compounds discussed in peptide forums, it has completed phase 3 development and is marketed as a prescription medicine in some countries.

Mechanism under study

Tesamorelin binds GHRH receptors in the anterior pituitary and stimulates pulsatile release of the body's own growth hormone, which in turn raises IGF-1. Because it acts upstream, feedback mechanisms such as somatostatin remain active — a pharmacological difference from administering growth hormone directly.

State of the human evidence

Randomised, placebo-controlled phase 3 trials in people living with HIV and abdominal fat accumulation showed a reduction in visceral adipose tissue of roughly 15 to 18 percent over 26 weeks compared with placebo. The effect largely reversed after stopping treatment. Later studies explored liver fat in people with HIV and non-alcoholic fatty liver disease, with encouraging but still limited results.

There is no robust evidence for use outside these populations, for example for general body composition, ageing or performance.

Risks and adverse effects

• Injection-site reactions, joint pain, muscle pain and peripheral swelling were among the most commonly reported effects.
• Raised IGF-1 and worsened glucose tolerance were observed, so the label calls for monitoring.
• The approved label contraindicates use in pregnancy, active malignancy and disorders of the hypothalamic-pituitary axis.

Limitations of the evidence

Reduction in visceral fat is a surrogate marker; the trials were not designed to show fewer cardiovascular events or longer survival. Long-term data on cancer risk, given the rise in IGF-1, remain limited.

Regulatory status by region

• United States: approved by the FDA in 2010 (brand Egrifta) to reduce excess abdominal fat in adults with HIV and lipodystrophy.
• European Union: an application to the EMA did not result in a marketing authorisation, so it is not an approved medicine in the EU.
• United Kingdom: no MHRA marketing authorisation at the time of writing.
• Growth hormone secretagogues are prohibited by the World Anti-Doping Agency.

Bottom line

Tesamorelin shows what a full regulatory path looks like: defined indication, controlled trials, a monitored safety profile. Research-grade material is not that medicine. For more on the GHRH family, see our tesamorelin research profile.